Landos Biopharma, Inc.
LABPDelisted May 23, 2024- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001785345
Landos Biopharma, Inc. was delisted on May 23, 2024; its insiders filed their last Form 4 on May 23, 2024; 16 institutions reported holding it in 13F filings for Q1 2024, worth $34.9M in total; no superinvestor held it.
13F holders, Q1 2023
Institutional positions in Landos Biopharma, Inc. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 20
- −3 vs. Q4 2022
- Shares held
- 15.5M
- −210.8K (−1.3%) vs. Q4 2022
- Total value
- $4.63M
- −$3.24M (−41.2%) vs. Q4 2022
- New holders
- 3
- 4 more added
- Sold out
- 6
- 7 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LABP on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 0 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 16 | $34.9M |
| Q4 2023 | 10 | $5.58M |
| Q3 2023 | 11 | $5.93M |
| Q2 2023 | 8 | $6.27M |
| Q1 2023 | 20 | $4.63M |
| Q4 2022 | 23 | $7.87M |
| Q3 2022 | 31 | $14.0M |
| Q2 2022 | 35 | $16.4M |
| Q1 2022 | 45 | $35.3M |
| Q4 2021 | 40 | $119.8M |
| Q3 2021 | 35 | $331.1M |
| Q2 2021 | 33 | $261.4M |
| Q1 2021 | 47 | $218.9M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Landos Biopharma, Inc.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | 14,869,915 | $4.43M | 0.13% | 00.0% | Unchanged |
| Macquarie Group Ltd | 147,182 | $44.0K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 91,538 | $27.3K | 0.00% | −699−0.8% | Reduced |
| Citadel Advisors LLC | 86,093 | $25.7K | 0.00% | +86,093 | New |
| Renaissance Technologies LLC | 79,201 | $24.0K | 0.00% | −46,200−36.8% | Reduced |
| Warberg Asset Management LLC | 73,504 | $21.9K | 0.01% | +73,504 | New |
| Bridgeway Capital Management, LLC | 39,000 | $11.6K | 0.00% | −60,000−60.6% | Reduced |
| BlackRock Inc. | 33,815 | $10.1K | 0.00% | +9,437+38.7% | Added |
| State Street Corp | 25,200 | $7.51K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 23,995 | $7.15K | 0.00% | −79,094−76.7% | Reduced |
| Tower Research Capital LLC (TRC) | 21,256 | $6.00K | 0.00% | +3,512+19.8% | Added |
| Susquehanna International Group, LLP | 14,976 | $4.46K | 0.00% | −6,088−28.9% | Reduced |
| Northern Trust Corp | 12,219 | $3.64K | 0.00% | 00.0% | Unchanged |
| Green Square Capital Advisors LLC | 10,000 | $2.98K | 0.00% | −84,500−89.4% | Reduced |
| UBS Group AG | 6,279 | $1.87K | 0.00% | +5,904+1,574.4% | Added |
| Wells Fargo & Company | 109 | $32 | 0.00% | +2+1.9% | Added |
| Bank of America Corp | 26 | $8 | 0.00% | +26 | New |
| JPMorgan Chase & Co | 611 | $0 | 0.00% | 00.0% | Unchanged |
| Acadian Asset Management LLC | 1,344 | $0 | 0.00% | 00.0% | Unchanged |
| Royal Bank of Canada | 103 | $0 | 0.00% | −276−72.8% | Reduced |
| HRT Financial LP | 0 | $0 | 0.00% | −52,564−100.0% | Sold out |
| Deutsche Bank AG | 0 | $0 | 0.00% | −41,760−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −14,826−100.0% | Sold out |
| FMR LLC | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −768−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −519−100.0% | Sold out |